Net Loss per Share - Schedule of computation of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Numerator
Net loss	$ (41,053)	$ (41,991)	$ (114,852)	$ (113,723)
Less: Net loss attributable to noncontrolling interest	$ (23,143)	$ (31,007)	$ (74,944)	$ (83,956)
Antidilutive securities
Earnout Rights			17,500,000	17,500,000
Stock options granted under the 2022 Equity Incentive Plan	22,076,832	17,356,148	22,076,832	17,356,148
Restricted Stock Rights [Member]
Antidilutive securities
Unvested Restricted Stock Rights			1,755,686	5,644,596
Common Class A [Member]
Numerator
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Basic	$ (17,910)	$ (10,984)	$ (39,908)	$ (29,767)
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Diluted	$ (17,910)	$ (10,984)	$ (39,908)	$ (29,767)
Denominator
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Basic	126,173,463	61,592,876	87,818,229	61,565,298
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Diluted	126,173,463	61,592,876	87,818,229	61,565,298
Net loss per share attributable to Class A ordinary shares, Basic	$ (0.14)	$ (0.18)	$ (0.45)	$ (0.48)
Net loss per share attributable to Class A ordinary shares, Diluted	$ (0.14)	$ (0.18)	$ (0.45)	$ (0.48)
Antidilutive securities
ProKidney Corp. ordinary shares	127,920,274		127,920,274		59,880,347
Common Class B [Member]
Antidilutive securities
ProKidney Corp. ordinary shares	163,741,676	173,839,330	163,741,676	173,839,330	168,297,916